Boundless Bio (NASDAQ:BOLD) reported a fourth-quarter loss of $0.58 per share, beating analyst expectations for a loss of $1.16 per share, as the clinical-stage oncology company began enrolling patients in the first-in-human study of its BBI-940 therapy.
The stock showed little movement in after-hours trading following the release of the results.
Net loss for the fourth quarter of 2025 came in at $12.9 million, an improvement from the $16.4 million loss recorded in the same period of 2024. Research and development expenses declined year over year to $9.8 million from $13.3 million, while general and administrative costs fell to $4.2 million from $5.0 million.
“With the KOMODO-1 trial of BBI-940 actively enrolling, we are excited to evaluate this potentially first-in-class oral Kinesin degrader in patients with breast cancer who are seeking new treatment options,” said Zachary Hornby, President and Chief Executive Officer of Boundless Bio.
In January 2026, the U.S. Food and Drug Administration accepted the company’s Investigational New Drug (IND) application for BBI-940, a novel selective oral Kinesin degrader.
The KOMODO-1 trial is now recruiting patients, focusing on individuals with ER+/HER2- breast cancer whose disease has progressed after treatment with CDK4/6 inhibitors, as well as patients with triple-negative breast cancer of the luminal androgen receptor subtype.
As of December 31, 2025, Boundless reported $107.6 million in cash, cash equivalents and short-term investments, compared with $152.1 million a year earlier.
The company said this cash position is expected to fund operations into the second half of 2028, including through the anticipated initial clinical proof-of-concept results from the KOMODO-1 study.
For the full year 2025, Boundless Bio recorded a net loss of $58.2 million, or $2.60 per share, compared with a net loss of $65.4 million, or $3.85 per share, in 2024.